Even as they have revolutionized the treatment of certain forms of cancer, CAR T-cell therapies have been shadowed by a significant limitation: many patients, including those whose cancer goes into full remission, eventually relapse. In a new study, Dana-Farber Cancer Institute researchers report on a technique with the potential to eliminate that problem.
Red Light Holland Announces NCIB Update and Live Q&A with CEO Todd Shapiro and CFO Jon Szczur on September 26th | Psychedelic Invest
Toronto, Ontario–(Newsfile Corp. – September 23, 2024) – Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) (“Red Light” or the “Company”), an Ontario-based
September 25, 2024